Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial

NCT06855095

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	The Netherlands Cancer Institute
Enrollment	39 participants

Key Eligibility Criteria

Inclusion (7)

- Age e 18 years;
- Able to provide spoken and written informed consent for the trial;
- Histopathological confirmed neuroendocrine tumor;
- Fulfill the clinical criteria for PRRT;
- At least one soft tissue lesion \> 2 cm;

... and 2 more (see full listing online)

Exclusion (5)

- Not possible to discontinue LA-SSA for 4-6 weeks;
- Use of short-acting SSAs;
- Pregnancy and lactating female patients;
- Inability to comply to the study procedures;
- Factors that might affect the biodistribution (for example, indication for furosemide directly after PRRT infusion, limited fluid intake, any renal catheters, etc.).

Locations (1 total)

Antoni van Leeuwenhoek, Amsterdam, Netherlands